Grufity logoGrufity logo
Stocks
Funds
Screener
Sectors
Watchlists
ARWR

ARWR - Arrowhead Pharmaceuticals Inc Stock Price, Fair Value and News

$65.61-1.30 (-1.94%)
Market Closed

44/100

ARWR

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

44/100

ARWR

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

Price Targets

Target 1Y

$58.67

Target 3M

$64.84

Target 6M

$62.69

ARWR Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

ARWR Price Action

Last 7 days

-2.9%

Last 30 days

-5.8%

Last 90 days

55.1%

Trailing 12 Months

227.6%

ARWR RSI Chart

ARWR Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

ARWR Valuation

Market Cap

8.9B

Price/Earnings (Trailing)

-2.2K

Price/Sales (Trailing)

10.74

EV/EBITDA

115.05

Price/Free Cashflow

56.8

ARWR Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

Price Targets

Target 1Y

$58.67

Target 3M

$64.84

Target 6M

$62.69

ARWR Fundamentals

ARWR Revenue

Revenue (TTM)

829.4M

Rev. Growth (Yr)

-30.15%

Rev. Growth (Qtr)

823.66%

ARWR Earnings

Earnings (TTM)

-4.0M

Earnings Growth (Yr)

87.3%

Earnings Growth (Qtr)

87.79%

ARWR Profitability

EBT Margin

6.21%

Return on Equity

-0.86%

Return on Assets

-0.29%

Free Cashflow Yield

1.76%

ARWR Investor Care

Shares Dilution (1Y)

9.14%

Diluted EPS (TTM)

-0.04

ARWR Alerts

  • 7 major insider sales recently.

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
202500829.4M0
20240000
2023272.8M256.2M240.7M0
2022263.4M249.9M243.2M278.3M
202189.1M107.6M138.3M144.4M
2020139.0M123.7M88.0M79.8M
201994.8M136.8M168.8M163.6M
201822.2M13.6M16.1M47.3M
201718.9M25.2M31.4M30.6M
2016255.0K170.8K6.4M12.7M
2015302.0K382.0K382.0K255.0K
2014175.0K175.0K175.0K302.0K
2013294.4K290.3K290.3K175.0K
201255.2K103.1K146.9K281.9K
201100296.1K24.0K
20100000
Get all data in R, Python etc through our Historical Stock Data APIs

About Arrowhead Pharmaceuticals Inc

ARWR
Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes ARO-AAT, a RNA interference (RNAi) therapeutic candidate that is in phase II clinical trial for the treatment of liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3, which is in phase 2b and one phase 3 clinical trial to treat hypertriglyceridemia; ARO-ANG3 that is in phase 2b clinical trial for the treatment of dyslipidemia; ARO-HSD, which is completed phase 1/2 clinical trial to treat liver diseases; ARO-ENaC2, which is in pre-clinical stage for the treatment of dyslipidemia cystic fibrosis; ARO-C3 that is in phase 1/2a clinical trial to reduce production of complement component 3; ARO-DUX4, which is in pre-clinical stage for the treatment of facioscapulohumeral muscular dystrophy; ARO-XDH that is in phase 1 clinical trial to treat uncontrolled gout; ARO-COV, which is in pre-clinical stage for the treatment of COVID-19; ARO-RAGE, which is in phase 1/2a clinical trial to treat muco-obstructive or inflammatory pulmonary conditions; and ARO-MMP7 that is in phase 1/2a clinical trial for treatment of idiopathic pulmonary fibrosis. It is also involved in the development of JNJ-3989, a subcutaneously administered RNAi therapeutic candidate to treat chronic hepatitis B virus infection; Olpasiran to reduce the production of apolipoprotein A; and ARO-AMG1 for treating genetically validated cardiovascular targets. Arrowhead Pharmaceuticals, Inc. has a license and research collaboration agreement with Janssen Pharmaceuticals, Inc. to develop JNJ-75220795, ARO-JNJ2, and ARO-JNJ3 RNAi therapeutics for liver-expressed targets; and license and research collaboration agreement with Takeda Pharmaceuticals U.S.A., Inc. to develop RNAi therapeutic candidate as a treatment for liver disease. Arrowhead Pharmaceuticals, Inc. was incorporated in 1989 and is headquartered in Pasadena, California.
 CEO
 WEBSITEhttps://arrowheadpharma.com
 SECTORHealthcare
 INDUSTRYBiotechnology
 EMPLOYEES397

Arrowhead Pharmaceuticals Inc Frequently Asked Questions

ARWR is the stock ticker symbol of Arrowhead Pharmaceuticals Inc. Every public company that trades on a stock exchange gets a ticker symbol.

As of Wed Jan 28 2026, market cap of Arrowhead Pharmaceuticals Inc is 8.91 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

You can check ARWR's fair value in chart for subscribers.

The fair value guage provides a quick view whether ARWR is over valued or under valued. Whether Arrowhead Pharmaceuticals Inc is cheap or expensive depends on the assumptions which impact Arrowhead Pharmaceuticals Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for ARWR.

As of Wed Jan 28 2026, ARWR's PE ratio (Price to Earnings) is -2234.04 and Price to Sales (PS) ratio is 10.74. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. ARWR PE ratio will change depending on the future growth rate expectations of investors.

In the past 10 years, Arrowhead Pharmaceuticals Inc has provided 0.341 (multiply by 100 for percentage) rate of return.